Clinical trial • Phase I • Oncology

JNJ-87562761 for Relapsed/Refractory Multiple Myeloma

Phase I trial of JNJ-87562761 for Relapsed/Refractory Multiple Myeloma. 65 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Relapsed/Refractory Multiple Myeloma
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
19-07-2024
First CTIS Authorization Date
11-10-2024

Trial design

Phase I trial across 5 sites in Spain.

Target Sample Size
65

Recruitment

Planned Sample Size
65
Recruitment Window Months
35

Geography

Total Number Of Sites
5
Total Number Of Participants
65

Spain

Earliest CTIS Part Ii Submission Date
20-09-2024
Latest Decision Or Authorization Date
11-12-2025
Processing Time Days
447
Number Of Sites
5
Number Of Participants
15

Sites

Site Name
Hospital Universitario Fundacion Jimenez Diaz
Department Name
Unidad de Ensayos Fase I
Contact Person Name
Gala Vega
Contact Person Email
Gala.vega@startmadrid.com
Site Name
Institut Catala D'oncologia
Department Name
Hemarología
Contact Person Name
Laura Abril
Contact Person Email
labril@iconcologia.net
Site Name
Clinica Universidad De Navarra
Department Name
Ensayos Clínicos de Hematología
Contact Person Name
Paula Rodriguez
Contact Person Email
paurodriguez@unav.es
Site Name
Hospital Universitario De Salamanca
Department Name
Ensayos Clinicos de Hematología
Contact Person Name
Maria Victoria Mateos
Contact Person Email
mvmateos@usal.es
Site Name
Hospital Clinic De Barcelona
Department Name
Hematología
Contact Person Name
Laura Rosiñol
Contact Person Email
lrosinol@clinic.cat

Sponsor

Primary sponsor

Full Name
Janssen Cilag International
Organisation Type
Pharmaceutical company
Country Of Registered Address
Belgium

Investigational products

Investigational Product Name
JNJ-87562761

Related trials

Other published trials that may interest you.